[1] White PL, Price JS, Backx M. Therapy and management of Pneumocystis jirovecii infection[J]. J Fungi (Basel), 2018, 4(4): 127. DOI: 10.3390/jof4040127.
[2] Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)[J]. Ann Hematol, 2021, 100(6): 1603-1620. DOI:10.1007/s00277-021-04452-9.
[3] Wang Y, Zhou X, Saimi M, et al. Risk factors of mortality from pneumocystis pneumonia in non-HIV patients: a meta-analysis[J]. Front Public Health, 2021, 9: 680108. DOI: 10.3389/fpubh.2021.680108.
[4] Bozzi G, Saltini P, Matera M, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients, a frequently overlooked problem. A case series from a large Italian center[J]. Int J Infect Dis, 2022, 121: 172-176. DOI: 10.1016/j.ijid.2022.05.024.
[5] 中国老年保健协会肺癌专业委员会,北京肿瘤学会肺癌专业委员会.老年晚期肺癌内科治疗中国专家共识(2022版)[J].中国肺癌杂志,2022,25(6):363-384. DOI:10.3779/j.issn.1009-3419.2022.101.25.
[6] 汪玉洁,陈锦秀.营养评价工具在肿瘤患者中的应用研究进展[J].中华护理杂志,2012,47(7):666-669. DOI:10.3761/j.issn.0254-1769.2012.07.035.
[7] 宫平,吴妮,支晨,等.营养干预联合情绪管理在晚期肺癌化疗过程中的应用研究[J].癌症进展,2020,18(3):311-313. DOI:10.11877/j.issn.1672-1535.2020.18.03.26.
[8] 倪隽.肺癌患者肺康复的临床实践证据[J].中国康复医学杂志,2018,33(6):626-629. DOI:10.3969/j.issn.1001-1242. 2018.06.002.
[9] 卢婷,倪隽.肺癌全周期康复探讨[J].中国医刊,2022,57(1):11-14. DOI:10.3969/j.issn.1008-1070.2022.01.004.
[10] Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients[J]. Am J Med, 2014, 127(12): 1242. e11- e17. DOI: 10.1016/j.amjmed.2014.07.010.
[11] Lee EH, Kim EY, Lee SH, et al. Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer[J]. Sci Rep, 2019, 9(1): 2094. DOI:10.1038/s41598-019-38618-3.
[12] Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia[J]. Respiration, 2018, 96(1): 52-65. DOI: 10.1159/000487713.
[13] Du CJ, Liu JY, Chen H, et al. Differences and similarities of high-resolution computed tomography features between pneumocystis pneumonia and cytomegalovirus pneumonia in AIDS patients[J]. Infect Dis Poverty, 2020, 9(1): 149. DOI: 10.1186/s40249-020-00768-2.
[14] 吕梦宇,裘关关,裘淼,等.放射性肺炎的诊疗研究进展[J].中国现代医生,2021,59(6):187-192.
[15] Duan J, Gao J, Liu Q, et al. Characteristics and prognostic factors of non-HIV immunocompromised patients with pneumocystis pneumonia diagnosed by metagenomics next-generation sequencing[J]. Front Med (Lausanne), 2022, 9: 812698. DOI: 10.3389/fmed.2022.812698.
[16] 孙国先,刘微丽,郑庆斌,等.肺泡灌洗液二代测序在重症肺炎病原菌未明患者中的应用[J].中国基层医药,2020,27(24):2951-2955. DOI:10.3760/cma.j.issn.1008-6706. 2020.24.003.
[17] 何小清,沈银忠.肺孢子菌肺炎诊治的研究进展[J].中国真菌学杂志,2018,13(4):247-251. DOI:10.3969/j.issn.1673- 3827.2018.04.013.
[18] Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother, 2016, 71(9): 2405-2413. DOI: 10.1093/jac/dkw158.
[19] Vogel MN, Vatlach M, Weissgerber P, et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients[J]. Eur J Radiol, 2012, 81(6): 1315-1320. DOI: 10.1016/j.ejrad.2011.02.052.
[20] 姜莉,冯玫,马珂,等.从老年多病共存患者看全科理念与人文关怀[J].中国药物与临床,2018,18(9):1605-1606. DOI:10.11655/zgywylc2018.09.063.
[21] 齐海梅.加强老年病患者的综合管理[J].中华老年医学杂志,2017,36(3):233. DOI:10.3760/cma.j.issn.0254-9026. 2017.03.001.
[22] 李晶,易炜娜.基于生物-心理-社会模式的一体化护理对自发性气胸患者肺功能恢复的影响[J].临床医学研究与实践,2022,7(14):159-161. DOI:10.19347/j.cnki.2096-1413. 202214044.
|